BRIEF-Cerus announces exercise of additional BARDA contract options for activities related to its planned Phase III trial of the Intercept Red Blood Cell System
December 19, 2016 at 08:59 AM EST
* Cerus Corp - Total value of full five-year contract has also increased to be worth up to $185 million in non-dilutive funding to Cerus
